Intravenous pamidronate in the treatment and prevention of osteoporosis

2004 ◽  
Vol 34 (4) ◽  
pp. 162-166 ◽  
Author(s):  
S. S. Y. Chan ◽  
L. M. Nery ◽  
A. McElduff ◽  
E. G. Wilmshurst ◽  
G. R. Fulcher ◽  
...  
Keyword(s):  
Treatment And Prevention ◽  
Intravenous Pamidronate ◽  
Prevention Of Osteoporosis

Osteoporosis and its treatment

1984 ◽  
Vol 22 (1) ◽  
pp. 1-4
Keyword(s):  
Young Adults ◽  
Unit Volume ◽  
Mineral Content ◽  
Bone Volume ◽  
Economic Consequences ◽  
Minor Trauma ◽  
Fractured Neck Of Femur ◽  
Neck Of Femur ◽  
Treatment And Prevention ◽  
Prevention Of Osteoporosis

The mineral content of bone is greatest in young adults and thereafter decreases with age. Osteoporosis can be defined as a reduction in the amount of bone mineral per unit volume of anatomical bone or skeleton, or more simply as a reduction in bone volume, exceeding the natural decline with age. The process diminishes bone strength but produces no symptoms until a fracture occurs in response to minor trauma - typically of a vertebral body, the proximal end of the femur or the lower forearm. Osteoporosis has major economic consequences: 10% of all orthopaedic beds in Britain are occupied by patients with fractured neck of femur, most of which are associated with osteoporosis.1 This article discusses the diagnosis, causes, treatment and prevention of osteoporosis.

Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis

2002 ◽  
Vol 13 (11) ◽  
pp. 841-857 ◽  
Author(s):  
N. Zethraeus ◽  
W. Ben Sedrine ◽  
F. Caulin ◽  
S. Corcaud ◽  
H. J. Gathon ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Treatment And Prevention ◽  
Prevention Of Osteoporosis ◽  
The Cost

scholarly journals Safety, Efficacy and Patient Acceptability of Bazedoxifene Acetate in the Management of Postmenopausal Osteoporosis

2012 ◽  
Vol 5 ◽  
pp. CMWH.S7308
Author(s):  
Tayane Muniz Fighera ◽  
Carolina Aguiar Moreira Kulak ◽  
Jaime Kulak Júnior
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Safety Concern ◽  
Patient Acceptability ◽  
Pharmacological Agents ◽  
Nonvertebral Fractures ◽  
Treatment And Prevention ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Prevention Of Osteoporosis ◽  
Post Hoc

Many pharmacological agents are available for treatment of postmenopausal osteoporosis, including estrogen and the selective modulators of estrogen receptor (SERMS). Bazedoxifene is a third-generation SERM, which acts as estrogen agonist in bone and lipid metabolism and as an antagonist in the breast and endometrium. Studies demonstrated that bazedoxifene reduced significantly the risk of vertebral fractures. In a subgroup of patients at high risk (post-hoc analysis), a reduction of nonvertebral fractures risk was reported. Moreover, the combination of conjugated estrogens with bazedoxifene seems to offer an alternative to classical hormone therapy, improving the vasomotor symptoms and vaginal atrophy, without the use of a progestin. Bazedoxifene is a promising drug for the treatment and prevention of osteoporosis in postmenopausal women; however a safety concern regarding venous thromboembolic events is needed before starting treatment.

scholarly journals Osteoporosis: 5G Technologies and 5P Medicine, Economic and Medico-Social Paradigms

2021 ◽  
Vol 7 (2) ◽  
pp. 163-178
Author(s):  
S. Bulgakova ◽  
I. Sirotko ◽  
P. Romanchuk
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Healthy Aging ◽  
Bone Cells ◽  
Medical Services ◽  
Multiple Chronic Conditions ◽  
Early Age ◽  
Protective Function ◽  
Treatment And Prevention ◽  
Prevention Of Osteoporosis

Currently, three main problems have been updated in gerontology and geriatrics: the first “early” is osteoporosis, the second “late” is Alzheimer’s disease, and the third “doubled” (comorbid, combined) is the presence of two diseases: Alzheimer’s disease and osteoporosis. The bone, in addition to mechanical and protective function, serves as a custodian of bone marrow cells and an organ for regulating the homeostasis of calcium ions. In the circadian gerontological period, osteoblasts, osteoclasts and osteocytes are determined by their respective functions of bone formation and bone resorption, and in the clinical-geriatric period of bone aging, bones and bone cells will change. 5P medicine and 5G medical services, new generation sequencing and pharmacogenetics are new modern foundations (paradigms) of personalized medicine — a key basis for understanding the common mechanisms of the pathogenesis of osteoporosis and Alzheimer’s disease. The presence of multiple chronic conditions in gerontology and geriatrics requires the use and clinical application of information and communication infrastructure 5G the next generation, neuromarketing and neurobial, neuroimaging consciousness and brain-machine interfaces, biorobots and biochips. 5P medicine and functioning of integrated neural systems through integration and analysis of dynamic hybrid multimodal neural EEG and fMRI information, combined with neuropsychological testing, will allow the geriatrician to manage (prevent and predict), not only healthy aging of Homo sapiens, but also timely diagnosis of osteoporosis and Alzheimer’s disease, treatment start time, definition. Early age (from 40–45 years) diagnosis, treatment and prevention of osteoporosis using tools (technologies) 5P medicine and 5G medical services, will manage the medical, socio-economic problem of our time. Early age diagnosis, treatment and prevention of osteoporosis using tools (technologies) 5P medicine and 5G medical services, allows you to manage a “silent epidemic” (“hidden epidemic”) of the 21st century with the help of non-medicamentous treatments — three multi-paradigm platforms: healthy lifestyle, physical activity, functional nutrition (balanced, healthy, natural). The key to the success of osteoporosis treatment is in a new 5P medicine based on a deep individualized approach and motivation to prevent diseases.

scholarly journals FEATURES OF MANAGEMENT IN PATIENTS WITH OSTEOPOROSIS AND DIABETES MELLITUS

2021 ◽  
Vol 77 (3) ◽  
pp. 111-119
Author(s):  
Larysa Zhuravlyova ◽  
Mariia Oliinyk ◽  
Yulia Sikalo
Keyword(s):  
Diabetes Mellitus ◽  
Diagnostic Methods ◽  
Complications Of Diabetes ◽  
Diagnosis Of Osteoporosis ◽  
Treatment And Prevention ◽  
Literary Sources ◽  
Number Of Patients ◽  
Patients With Diabetes ◽  
Prevention Of Osteoporosis

The number of patients with diabetes mellitus in the world has been progressively increasing in recent years, therefore, the fight against complications of diabetes mellitus is an important problem of our time. The purpose of our review is to analyze the literature data on the risks of osteoporosis in patients with diabetes mellitus, effective diagnostic methods, as well as current recommendations for the treatment and prevention of osteoporosis in this category of patients. Results. We have processed and analyzed literary sources and internationalrecommendations, which identify the main mechanisms and risk factors that contribute to the development of osteoporosis in patients with type 1 and 2 diabetes mellitus; methods for the timely diagnosis of osteoporosis are indicated, methods for correcting the condition of patients with diabetes mellitus, which can help prevent the development of osteoporosis in this group of patients, are given. The current recommendations for the treatment of osteoporosis in men and women are presented. Conclusions. Taking into account the data of the analysis of literary sources, osteoporosis can be considered one of the complications of diabetes mellitus. Today, densitometry and fracture risk assessment FRAX are quite sensitive methods for early diagnosis of osteoporosis in patients with type 1 diabetes mellitus, but not sufficient for patients with type 2 diabetes mellitus, therefore there is a need to determine the trabecular bone index during densitometry, as well as additional actions when assessing the risk of fractures on the FRAX scale. Therapy of patients with osteoporosis with concomitant diabetes mellitus should be based on the achievement of target glycemic levels and the use of bisphosphonates with target level of calcium and vitamin D.

scholarly journals Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab

2021 ◽  
pp. 185-191
Author(s):  
O. V. Yakushevskaya
Keyword(s):  
Zoledronic Acid ◽  
Vertebral Fractures ◽  
Bone Matrix ◽  
Term Therapy ◽  
Antiresorptive Therapy ◽  
Treatment And Prevention ◽  
Increased Risk ◽  
Antiresorptive Drugs ◽  
Prevention Of Osteoporosis ◽  
Russian Association

In accordance with the data of the Federal Clinical Recommendations for the Diagnosis, Treatment and Prevention of Osteoporosis, with the latter, antiresorptive drugs (denosumab, bisphosphonates) are used, which mainly suppress bone resorption, and anabolic compounds (teriparatide), which enhance bone formation. The vector of their pharmacological effect helps to prevent BMD loss and significantly reduces the risk of low-energy vertebral fractures and fractures of other localizations. The experience of clinical trials makes it possible to successfully carry out antiresorptive therapy with some drugs (denosumab) for up to 10 years, demonstrating good adherence and tolerance. Bisphosphonates remain in the bone matrix for a long time and are characterized by a period of a certain aftereffect. Denosumab and teriparatide show their effect only during the period of direct use. According to some data, when denosumab therapy is canceled in a situation where the targeted goal is achieved, the incidence of vertebral fractures increases, especially in patients with a history of low-traumatic fractures. The article will present the main provisions of the European Calcified Tissues Society, the European Medical Agency, the Russian Association for Osteoporosis regarding the timing of treatment and an analysis of clinical situations requiring the appointment of alternative antiresorptive therapy. According to the resolution of the Council of Experts of the Russian Association on Osteoporosis, bisphosphonates are recommended for all patients to prevent an increased risk of vertebral fractures 6 months after patients had their last subcutaneous injection of denosumab. Oral bisphosphonates should be taken immediately, and zoledronic acid injection should be delayed for another 65 days following a missed denosumab injection.

The Use of Preventive Strategies for Bone Loss

2005 ◽  
Vol 33 (02) ◽  
pp. 299-306 ◽  
Author(s):  
Hong Xu ◽  
David Lawson ◽  
Annette Kras ◽  
Damien Ryan
Keyword(s):  
Bone Loss ◽  
Preventive Strategies ◽  
Common Pattern ◽  
Yin Deficiency ◽  
Treatment And Prevention ◽  
Tai Ji ◽  
Prevention And Treatment ◽  
Prevention Of Osteoporosis ◽  
Research Findings ◽  
Global Population

Osteoporosis is a worldwide problem that is increasing significantly as the global population both increases and ages. While osteoporosis has been extensively studied in recent years, the utilization of traditional Chinese medicine (TCM) for the diagnosis, prevention and treatment of this condition has seldom been examined. This paper examines the theories and the literature that relate to diagnosis, prevention and treatment of bone loss at the time of menopause according to the principles of TCM. It also considers practical developments in these areas as illustrated by the authors' research findings in recent studies. TCM diagnosis attributes a number of different underlying patterns to menopausal bone loss. A very common pattern in this situation is a Kidney qi and yin deficiency pattern. TCM analysis can be used as an early determinant of those persons who are potentially at risk of bone loss. Acupuncture, herbal medicine and Tai Ji exercise can then be applied to prevent and treat osteoporosis. These treatments can be effective, if they are applied correctly. The therapies may also be used in the treatment and prevention of osteoporosis, as well as the general maintenance of women's health during menopause.

Sign in / Sign up

Export Citation Format

Share Document